These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 16412658)

  • 1. Visual deficits in a mouse model of Batten disease are the result of optic nerve degeneration and loss of dorsal lateral geniculate thalamic neurons.
    Weimer JM; Custer AW; Benedict JW; Alexander NA; Kingsley E; Federoff HJ; Cooper JD; Pearce DA
    Neurobiol Dis; 2006 May; 22(2):284-93. PubMed ID: 16412658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retinal pathology and function in a Cln3 knockout mouse model of juvenile Neuronal Ceroid Lipofuscinosis (batten disease).
    Seigel GM; Lotery A; Kummer A; Bernard DJ; Greene ND; Turmaine M; Derksen T; Nussbaum RL; Davidson B; Wagner J; Mitchison HM
    Mol Cell Neurosci; 2002 Apr; 19(4):515-27. PubMed ID: 11988019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optic nerve degeneration in a murine model of juvenile ceroid lipofuscinosis.
    Sappington RM; Pearce DA; Calkins DJ
    Invest Ophthalmol Vis Sci; 2003 Sep; 44(9):3725-31. PubMed ID: 12939285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Further Characterization of the Predominant Inner Retinal Degeneration of Aging Cln3
    Volz C; Mirza M; Langmann T; Jägle H
    Adv Exp Med Biol; 2018; 1074():403-411. PubMed ID: 29721970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A knock-in reporter mouse model for Batten disease reveals predominant expression of Cln3 in visual, limbic and subcortical motor structures.
    Ding SL; Tecedor L; Stein CS; Davidson BL
    Neurobiol Dis; 2011 Feb; 41(2):237-48. PubMed ID: 20875858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of CLN3, the gene mutated in juvenile neuronal ceroid lipofuscinosis, leads to metabolic impairment and autophagy induction in retinal pigment epithelium.
    Zhong Y; Mohan K; Liu J; Al-Attar A; Lin P; Flight RM; Sun Q; Warmoes MO; Deshpande RR; Liu H; Jung KS; Mitov MI; Lin N; Butterfield DA; Lu S; Liu J; Moseley HNB; Fan TWM; Kleinman ME; Wang QJ
    Biochim Biophys Acta Mol Basis Dis; 2020 Oct; 1866(10):165883. PubMed ID: 32592935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcript and in silico analysis of CLN3 in juvenile neuronal ceroid lipofuscinosis and associated mouse models.
    Chan CH; Mitchison HM; Pearce DA
    Hum Mol Genet; 2008 Nov; 17(21):3332-9. PubMed ID: 18678598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histopathologic and immunocytochemical analysis of the retina and ocular tissues in Batten disease.
    Bensaoula T; Shibuya H; Katz ML; Smith JE; Johnson GS; John SK; Milam AH
    Ophthalmology; 2000 Sep; 107(9):1746-53. PubMed ID: 10964839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thalamocortical neuron loss and localized astrocytosis in the Cln3Deltaex7/8 knock-in mouse model of Batten disease.
    Pontikis CC; Cotman SL; MacDonald ME; Cooper JD
    Neurobiol Dis; 2005 Dec; 20(3):823-36. PubMed ID: 16006136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunomodulation with minocycline rescues retinal degeneration in juvenile neuronal ceroid lipofuscinosis mice highly susceptible to light damage.
    Dannhausen K; Möhle C; Langmann T
    Dis Model Mech; 2018 Sep; 11(9):. PubMed ID: 30042155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-invasive assessment of retinal alterations in mouse models of infantile and juvenile neuronal ceroid lipofuscinosis by spectral domain optical coherence tomography.
    Groh J; Stadler D; Buttmann M; Martini R
    Acta Neuropathol Commun; 2014 May; 2():54. PubMed ID: 24887158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel interactions of CLN3 protein link Batten disease to dysregulation of fodrin-Na+, K+ ATPase complex.
    Uusi-Rauva K; Luiro K; Tanhuanpää K; Kopra O; Martín-Vasallo P; Kyttälä A; Jalanko A
    Exp Cell Res; 2008 Sep; 314(15):2895-905. PubMed ID: 18621045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Large-scale phenotyping of an accurate genetic mouse model of JNCL identifies novel early pathology outside the central nervous system.
    Staropoli JF; Haliw L; Biswas S; Garrett L; Hölter SM; Becker L; Skosyrski S; Da Silva-Buttkus P; Calzada-Wack J; Neff F; Rathkolb B; Rozman J; Schrewe A; Adler T; Puk O; Sun M; Favor J; Racz I; Bekeredjian R; Busch DH; Graw J; Klingenspor M; Klopstock T; Wolf E; Wurst W; Zimmer A; Lopez E; Harati H; Hill E; Krause DS; Guide J; Dragileva E; Gale E; Wheeler VC; Boustany RM; Brown DE; Breton S; Ruether K; Gailus-Durner V; Fuchs H; de Angelis MH; Cotman SL
    PLoS One; 2012; 7(6):e38310. PubMed ID: 22701626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Age-dependent alterations in neuronal activity in the hippocampus and visual cortex in a mouse model of Juvenile Neuronal Ceroid Lipofuscinosis (CLN3).
    Burkovetskaya M; Karpuk N; Kielian T
    Neurobiol Dis; 2017 Apr; 100():19-29. PubMed ID: 28042098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel CLN3 mutation predicted to cause complete loss of protein function does not modify the classical JNCL phenotype.
    Kwon JM; Rothberg PG; Leman AR; Weimer JM; Mink JW; Pearce DA
    Neurosci Lett; 2005 Oct; 387(2):111-4. PubMed ID: 16087292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebellar defects in a mouse model of juvenile neuronal ceroid lipofuscinosis.
    Weimer JM; Benedict JW; Getty AL; Pontikis CC; Lim MJ; Cooper JD; Pearce DA
    Brain Res; 2009 Apr; 1266():93-107. PubMed ID: 19230832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using Patient-Specific Induced Pluripotent Stem Cells and Wild-Type Mice to Develop a Gene Augmentation-Based Strategy to Treat CLN3-Associated Retinal Degeneration.
    Wiley LA; Burnight ER; Drack AV; Banach BB; Ochoa D; Cranston CM; Madumba RA; East JS; Mullins RF; Stone EM; Tucker BA
    Hum Gene Ther; 2016 Oct; 27(10):835-846. PubMed ID: 27400765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenotyping heterozygous carriers of juvenile neuronal ceroid lipofuscinosis with CLN3 mutations.
    Bergholz R; Kohlschütter A; Schulz A; Hubert W; Rüther K
    Graefes Arch Clin Exp Ophthalmol; 2015 Aug; 253(8):1245-50. PubMed ID: 25338278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Profound infantile neuroretinal dysfunction in a heterozygote for the CLN3 genetic defect.
    de los Reyes E; Dyken PR; Phillips P; Brodsky M; Bates S; Glasier C; Mrak RE
    J Child Neurol; 2004 Jan; 19(1):42-6. PubMed ID: 15032383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Self-Complementary AAV9 Gene Delivery Partially Corrects Pathology Associated with Juvenile Neuronal Ceroid Lipofuscinosis (CLN3).
    Bosch ME; Aldrich A; Fallet R; Odvody J; Burkovetskaya M; Schuberth K; Fitzgerald JA; Foust KD; Kielian T
    J Neurosci; 2016 Sep; 36(37):9669-82. PubMed ID: 27629717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.